Asset profile

Azacitidine

Small molecule

ApprovedDNMT1 (DNA methyltransferase 1)
Approvedregulatory verdict

Evidence outlook

Approved — Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(119 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (24)
August 2026 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2026-08-31 · NCT05554419 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-09-01 · NCT06561880 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Monocytic Leukemia, Newly DiagnosedRecruiting
Est. primary completion 2026-09-30 · NCT05566054 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (5)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-10 · NCT07163793 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-10 · NCT06022003 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-10-01 · NCT06611839 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Solid Tumor, Gastrointestinal Cancer, Breast CancerRecruiting
Est. primary completion 2026-10-04 · NCT05381038 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-10-31 · NCT06741722 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-11 · NCT03850574 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2026-11-15 · NCT05226455 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Plasmacytoma, Plasmacytoma of Bone, Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-19 · NCT04174196 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (13)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT05788679 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06783790 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06379360 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06635681 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Safety, Antitumor Activity, PK ProfileActive not recruiting
Est. primary completion 2026-12-01 · NCT06858618 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Hematologic MalignanciesRecruiting
Est. primary completion 2026-12-30 · NCT04588922 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT00392353 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT04128501 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT05603884 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06345365 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07486479 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (39)
January 2027 (5)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01 · NCT06384261 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06773208 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-01 · NCT04801797 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-01-01 · NCT06754540 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-31 · NCT03862157 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (3)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04086264 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02 · NCT05183035 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02-28 · NCT03383575 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (3)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT05428969 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT05554406 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)
Phase 2Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, NosRecruiting
Est. primary completion 2027-04-01 · NCT07012447 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04-30 · NCT03586609 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 2Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast CarcinomaRecruiting
Est. primary completion 2027-05 · NCT04891068 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT04988555 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT06429098 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08-30 · NCT07132684 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (5)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-01 · NCT07743112 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-20 · NCT03683433 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT03471260 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT05401097 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (5)
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-10 · NCT07486726 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10 · NCT06511882 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-11 · NCT06504459 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-15 · NCT05907057 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-10-31 · NCT06497062 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-01 · NCT04256317 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (9)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12 · NCT04581512 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12 · NCT06470841 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12 · NCT07255872 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06548230 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-01 · NCT06744556 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT07304011 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05270200 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07748455 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05554393 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (28)
January 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01 · NCT07392242 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (4)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-02-01 · NCT07407660 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-02-08 · NCT04771130 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-02-09 · NCT06456463 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Myeloid MalignancyRecruiting
Est. primary completion 2028-02-20 · NCT03850418 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (3)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-03 · NCT06014489 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-03-31 · NCT07507825 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-03-31 · NCT07469046 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-04-01 · NCT07514832 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (2)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-25 · NCT06389292 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-05-31 · NCT07664839 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (4)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT07471841 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT06668558 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT05404906 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06-01 · NCT07642453 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (3)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-07 · NCT07605949 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-31 · NCT05520567 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-31 · NCT06664879 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (3)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09 · NCT04501120 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09 · NCT05904106 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-01 · NCT04140487 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07425808 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-11-01 · NCT06557421 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-11-26 · NCT07425782 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (4)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT03013998 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12 · NCT07060001 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12-11 · NCT07646821 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07148180 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (13)
January 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT06084819 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2029 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07407140 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-03-31 · NCT06782542 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-04 · NCT06696183 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT06317649 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (2)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-06 · NCT07575412 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-22 · NCT06852222 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07754799 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07755202 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (3)
Phase 2/3Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2029-12 · NCT07651163 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2029-12 · NCT07651176 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-12-12 · NCT07508982 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (12)
April 2030 (3)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT07478991 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07539818 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-04-30 · NCT07770698 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (3)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-06 · NCT07562568 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06 · NCT07078591 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06-01 · NCT07672262 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2030 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-07-21 · NCT05442216 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2030 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-08-10 · NCT07686965 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (3)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT06598384 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT07463768 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Leukemia, B-Cell, Chronic, LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT07082452 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2030 (1)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2030-10-31 · NCT04062266 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (2)
May 2031 (1)
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-05-31 · NCT07623187 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2031 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
May 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-05 · NCT07581002 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.

Educational data tool. Grades describe evidence quality, not investment merit.